Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis.

Giles JT, Bartlett SJ, Gelber AC, Nanda S, Fontaine K, Ruffing V, Bathon JM.

Arthritis Rheum. 2006 Apr 15;55(2):333-7. No abstract available.

2.

Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study.

den Broeder AA, Creemers MC, Fransen J, de Jong E, de Rooij DJ, Wymenga A, de Waal-Malefijt M, van den Hoogen FH.

J Rheumatol. 2007 Apr;34(4):689-95.

PMID:
17117492
3.

Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis.

Schneeweiss S, Setoguchi S, Weinblatt ME, Katz JN, Avorn J, Sax PE, Levin R, Solomon DH.

Arthritis Rheum. 2007 Jun;56(6):1754-64.

4.

Nonserious infections: should there be cause for serious concerns?

Dao KH, Herbert M, Habal N, Cush JJ.

Rheum Dis Clin North Am. 2012 Nov;38(4):707-25. doi: 10.1016/j.rdc.2012.08.016. Review.

PMID:
23137578
5.

Tumour necrosis factor inhibitors--what we need to know.

Hasan U.

N Z Med J. 2006 Dec 1;119(1246):U2336. Review.

PMID:
17151710
6.

Sarcoidosis during anti-tumor necrosis factor-alpha therapy: no relapse after rechallenge.

van der Stoep D, Braunstahl GJ, van Zeben J, Wouters J.

J Rheumatol. 2009 Dec;36(12):2847-8. doi: 10.3899/jrheum.090307. No abstract available.

PMID:
19966199
7.

Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety.

Komano Y, Tanaka M, Nanki T, Koike R, Sakai R, Kameda H, Nakajima A, Saito K, Takeno M, Atsumi T, Tohma S, Ito S, Tamura N, Fujii T, Sawada T, Ida H, Hashiramoto A, Koike T, Ishigatsubo Y, Eguchi K, Tanaka Y, Takeuchi T, Miyasaka N, Harigai M; REAL Study Group.

J Rheumatol. 2011 Jul;38(7):1258-64. doi: 10.3899/jrheum.101009. Epub 2011 Apr 15.

PMID:
21498482
8.

Tumor necrosis factor inhibition: a part of the solution or a part of the problem of heart failure in rheumatoid arthritis?

Gabriel SE.

Arthritis Rheum. 2008 Mar;58(3):637-40. doi: 10.1002/art.23280. No abstract available.

9.

Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry.

Atzeni F, Sarzi-Puttini P, Botsios C, Carletto A, Cipriani P, Favalli EG, Frati E, Foschi V, Gasparini S, Giardina A, Gremese E, Iannone F, Sebastiani M, Ziglioli T, Biasi D, Ferri C, Galeazzi M, Gerli R, Giacomelli R, Gorla R, Govoni M, Lapadula G, Marchesoni A, Salaffi F, Punzi L, Triolo G, Ferraccioli G.

Autoimmun Rev. 2012 Dec;12(2):225-9. doi: 10.1016/j.autrev.2012.06.008. Epub 2012 Jul 13.

PMID:
22796281
10.

Unstable diabetes in a patient receiving anti-TNF-alpha for rheumatoid arthritis.

Boulton JG, Bourne JT.

Rheumatology (Oxford). 2007 Jan;46(1):178-9. Epub 2006 Sep 23. No abstract available.

PMID:
16998233
11.

Anti-tumor necrosis factor-alpha agents for rheumatoid arthritis: assessing longterm safety.

Hyrich KL, Silman AJ.

J Rheumatol. 2006 May;33(5):831-3. No abstract available.

PMID:
16652412
12.

[TNF inhibitors for treatment of rheumatoid arthritis].

Otomo K, Koike T.

Nihon Naika Gakkai Zasshi. 2008 Oct 10;97(10):2405-12. Review. Japanese. No abstract available.

PMID:
19149036
13.

Coxiella burnetii infection (Q fever) in rheumatoid arthritis patients with and without anti-TNFα therapy.

Schoffelen T, Kampschreur LM, van Roeden SE, Wever PC, den Broeder AA, Nabuurs-Franssen MH, Sprong T, Joosten LA, van Riel PL, Oosterheert JJ, van Deuren M, Creemers MC.

Ann Rheum Dis. 2014 Jul;73(7):1436-8. doi: 10.1136/annrheumdis-2014-205455. Epub 2014 May 2. No abstract available.

PMID:
24794150
14.

[Adverse effects of biologic agents in treatment of rheumatoid arthritis--prevention of tuberculosis].

Tomono K, Hashimoto S.

Nihon Rinsho. 2005 Jan;63 Suppl 1:573-8. Review. Japanese. No abstract available.

PMID:
15799420
15.

Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis?

Listing J, Strangfeld A, Kekow J, Schneider M, Kapelle A, Wassenberg S, Zink A.

Arthritis Rheum. 2008 Mar;58(3):667-77. doi: 10.1002/art.23281.

16.

[TNF targetting therapy for rheumatoid arthritis].

Takeuchi T.

Nihon Naika Gakkai Zasshi. 2006 Sep 10;95(9):1787-94. Review. Japanese. No abstract available.

PMID:
17037316
17.

New drugs for rheumatoid arthritis.

Olsen NJ, Stein CM.

N Engl J Med. 2004 May 20;350(21):2167-79. Review. No abstract available.

PMID:
15152062
18.

Anti-tumor necrosis factor alpha switching in rheumatoid arthritis and juvenile chronic arthritis.

Favalli EG, Arreghini M, Arnoldi C, Panni B, Marchesoni A, Tosi S, Pontikaki I.

Arthritis Rheum. 2004 Apr 15;51(2):301-2. No abstract available.

19.

Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.

Dewedar AM, Shalaby MA, Al-Homaid S, Mahfouz AM, Shams OA, Fathy A.

Int J Rheum Dis. 2012 Jun;15(3):330-5. doi: 10.1111/j.1756-185X.2012.01715.x. Epub 2012 Feb 13.

PMID:
22709496
20.

Supplemental Content

Support Center